ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 001675

Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease

Identifieur interne : 001675 ( PascalFrancis/Curation ); précédent : 001674; suivant : 001676

Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease

Auteurs : S. Holemans [Belgique] ; F. Javoy-Agid [France] ; Y. Agid [France] ; F. De Paermentier ; E. C. Laterre [Belgique] ; J.-M. Maloteaux [Belgique]

Source :

Brain research [ 0006-8993 ] ; 1994.

RBID : Pascal:94-0457002

Descripteurs français

Pascal (Inist)
- Site fixation, Encéphale, Sulfonylurées, Parkinson maladie, Chorée Huntington, Paralysie susnucléaire, Exploration, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Binding site, Brain (vertebrata), Exploration, Human, Huntington disease, Parkinson disease, Sulfonylureas, Supranuclear paralysis.

Abstract

In human brain, [³H]glibenclamide binds with high affinity (K_D about 3.5 nM) to sulfonylurea binding sites which are associated with ATP-sensitive potassium (K_ATP) channels. Regarding to the important neuromodulatory action of K_ATP channels in some neuronal populations, sulfonylurea binding sites were measured in several cortical areas (frontal and temporal cortex, hippocampus) and striatum (caudate nucleus and putamen) in controls and patients with Parkinson's disease or progressive supranuclear palsy. There was no modification of [³H]glibenclamide specific binding in the cerebral regions studied in both pathologies

A01	`01`	`1`		`@0 0006-8993`
A02	`01`			`@0 BRREAP`
A03		`1`		`@0 Brain res.`
A05				`@2 642`
A06				`@2 1-2`
A08	`01`	`1`	`ENG`	`@1 Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease`
A11	`01`	`1`		`@1 HOLEMANS (S.)`
A11	`02`	`1`		`@1 JAVOY-AGID (F.)`
A11	`03`	`1`		`@1 AGID (Y.)`
A11	`04`	`1`		`@1 DE PAERMENTIER (F.)`
A11	`05`	`1`		`@1 LATERRE (E. C.)`
A11	`06`	`1`		`@1 MALOTEAUX (J.-M.)`
A14	`01`			`@1 Univ. catholique Louvain, lab. neurochimie @2 1200 Brussels @3 BEL @Z 1 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 INSERM CHU Pitié-Salpêtrière, lab. médecine exp. @2 75651 Paris @3 FRA @Z 2 aut. @Z 3 aut.`
A20				`@1 327-333`
A21				`@1 1994`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 12895 @5 354000049566610400`
A44				`@0 0000`
A45				`@0 47 ref.`
A47	`01`	`1`		`@0 94-0457002`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Brain research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 In human brain, [³H]glibenclamide binds with high affinity (K_D about 3.5 nM) to sulfonylurea binding sites which are associated with ATP-sensitive potassium (K_ATP) channels. Regarding to the important neuromodulatory action of K_ATP channels in some neuronal populations, sulfonylurea binding sites were measured in several cortical areas (frontal and temporal cortex, hippocampus) and striatum (caudate nucleus and putamen) in controls and patients with Parkinson's disease or progressive supranuclear palsy. There was no modification of [³H]glibenclamide specific binding in the cerebral regions studied in both pathologies
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Site fixation @5 01`
C03	`01`	`X`	`ENG`	`@0 Binding site @5 01`
C03	`01`	`X`	`SPA`	`@0 Sitio fijación @5 01`
C03	`02`	`X`	`FRE`	`@0 Encéphale @5 02`
C03	`02`	`X`	`ENG`	`@0 Brain (vertebrata) @5 02`
C03	`02`	`X`	`SPA`	`@0 Encéfalo @5 02`
C03	`03`	`X`	`FRE`	`@0 Sulfonylurées @5 03`
C03	`03`	`X`	`ENG`	`@0 Sulfonylureas @5 03`
C03	`03`	`X`	`SPA`	`@0 Sulfonilureas @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Chorée Huntington @2 NM @5 05`
C03	`05`	`X`	`ENG`	`@0 Huntington disease @2 NM @5 05`
C03	`05`	`X`	`SPA`	`@0 Corea Huntington @2 NM @5 05`
C03	`06`	`X`	`FRE`	`@0 Paralysie susnucléaire @2 NM @5 06`
C03	`06`	`X`	`ENG`	`@0 Supranuclear paralysis @2 NM @5 06`
C03	`06`	`X`	`SPA`	`@0 Parálisis supranuclear @2 NM @5 06`
C03	`07`	`X`	`FRE`	`@0 Exploration @5 09`
C03	`07`	`X`	`ENG`	`@0 Exploration @5 09`
C03	`07`	`X`	`SPA`	`@0 Exploración @5 09`
C03	`08`	`X`	`FRE`	`@0 Homme @5 41`
C03	`08`	`X`	`ENG`	`@0 Human @5 41`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 41`
C07	`01`	`X`	`FRE`	`@0 Système nerveux central @5 20`
C07	`01`	`X`	`ENG`	`@0 Central nervous system @5 20`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso central @5 20`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 26`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 26`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 26`
C07	`03`	`X`	`FRE`	`@0 Système nerveux pathologie @5 27`
C07	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 27`
C07	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 27`
C07	`04`	`X`	`FRE`	`@0 Maladie héréditaire @5 30`
C07	`04`	`X`	`ENG`	`@0 Genetic disease @5 30`
C07	`04`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 30`
N21				`@1 208`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001977

Links to Exploration step

Pascal:94-0457002

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease</title>
<author><name sortKey="Holemans, S" sort="Holemans, S" uniqKey="Holemans S" first="S." last="Holemans">S. Holemans</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM CHU Pitié-Salpêtrière, lab. médecine exp.</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM CHU Pitié-Salpêtrière, lab. médecine exp.</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="De Paermentier, F" sort="De Paermentier, F" uniqKey="De Paermentier F" first="F." last="De Paermentier">F. De Paermentier</name>
</author>
<author><name sortKey="Laterre, E C" sort="Laterre, E C" uniqKey="Laterre E" first="E. C." last="Laterre">E. C. Laterre</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Maloteaux, J M" sort="Maloteaux, J M" uniqKey="Maloteaux J" first="J.-M." last="Maloteaux">J.-M. Maloteaux</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0457002</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0457002 INIST</idno>
<idno type="RBID">Pascal:94-0457002</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001977</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001675</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease</title>
<author><name sortKey="Holemans, S" sort="Holemans, S" uniqKey="Holemans S" first="S." last="Holemans">S. Holemans</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM CHU Pitié-Salpêtrière, lab. médecine exp.</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM CHU Pitié-Salpêtrière, lab. médecine exp.</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="De Paermentier, F" sort="De Paermentier, F" uniqKey="De Paermentier F" first="F." last="De Paermentier">F. De Paermentier</name>
</author>
<author><name sortKey="Laterre, E C" sort="Laterre, E C" uniqKey="Laterre E" first="E. C." last="Laterre">E. C. Laterre</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Maloteaux, J M" sort="Maloteaux, J M" uniqKey="Maloteaux J" first="J.-M." last="Maloteaux">J.-M. Maloteaux</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="1994">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Binding site</term>
<term>Brain (vertebrata)</term>
<term>Exploration</term>
<term>Human</term>
<term>Huntington disease</term>
<term>Parkinson disease</term>
<term>Sulfonylureas</term>
<term>Supranuclear paralysis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Site fixation</term>
<term>Encéphale</term>
<term>Sulfonylurées</term>
<term>Parkinson maladie</term>
<term>Chorée Huntington</term>
<term>Paralysie susnucléaire</term>
<term>Exploration</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In human brain, [<sup>3</sup>
H]glibenclamide binds with high affinity (K<sub>D</sub>
 about 3.5 nM) to sulfonylurea binding sites which are associated with ATP-sensitive potassium (K<sub>ATP</sub>
) channels. Regarding to the important neuromodulatory action of K<sub>ATP</sub>
 channels in some neuronal populations, sulfonylurea binding sites were measured in several cortical areas (frontal and temporal cortex, hippocampus) and striatum (caudate nucleus and putamen) in controls and patients with Parkinson's disease or progressive supranuclear palsy. There was no modification of [<sup>3</sup>
H]glibenclamide specific binding in the cerebral regions studied in both pathologies</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8993</s0>
</fA01>
<fA02 i1="01"><s0>BRREAP</s0>
</fA02>
<fA03 i2="1"><s0>Brain res.</s0>
</fA03>
<fA05><s2>642</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HOLEMANS (S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JAVOY-AGID (F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DE PAERMENTIER (F.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LATERRE (E. C.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MALOTEAUX (J.-M.)</s1>
</fA11>
<fA14 i1="01"><s1>Univ. catholique Louvain, lab. neurochimie</s1>
<s2>1200 Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>INSERM CHU Pitié-Salpêtrière, lab. médecine exp.</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>327-333</s1>
</fA20>
<fA21><s1>1994</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>12895</s2>
<s5>354000049566610400</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>47 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>94-0457002</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In human brain, [<sup>3</sup>
H]glibenclamide binds with high affinity (K<sub>D</sub>
 about 3.5 nM) to sulfonylurea binding sites which are associated with ATP-sensitive potassium (K<sub>ATP</sub>
) channels. Regarding to the important neuromodulatory action of K<sub>ATP</sub>
 channels in some neuronal populations, sulfonylurea binding sites were measured in several cortical areas (frontal and temporal cortex, hippocampus) and striatum (caudate nucleus and putamen) in controls and patients with Parkinson's disease or progressive supranuclear palsy. There was no modification of [<sup>3</sup>
H]glibenclamide specific binding in the cerebral regions studied in both pathologies</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Site fixation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Binding site</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sitio fijación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Sulfonylurées</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Sulfonylureas</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sulfonilureas</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chorée Huntington</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Huntington disease</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Paralysie susnucléaire</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Supranuclear paralysis</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Parálisis supranuclear</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Exploration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Exploration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Exploración</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>41</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>41</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>41</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>26</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>26</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>26</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>27</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>27</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>27</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>30</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>30</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>30</s5>
</fC07>
<fN21><s1>208</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001675 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001675 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:94-0457002
   |texte=   Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease

Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri